Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial...
Q1 2026
May 18, 2026
FY 2025
Mar 18, 2026
Q4 2025
Q3 2025
Nov 12, 2025
Q2 2025
Aug 12, 2025